Source: Omar, A. I. Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma. J. Vis. Exp. (2014)
This video demonstrates the application of Tumor Treating Fields or TTFields in human brain tumor models. This non-invasive technique delivers low-intensity alternating electric fields directly to the brain, resulting in inhibition of cell division and subsequent apoptosis.
All procedures involving human participants have been performed in compliance with the institutional, national, and international guidelines for human welfare and have been reviewed by the local institutional review board.
1. Application of the TTF System
NOTE: The system consists of the following components: an electric field generator (the Device), a connection cable and box, a portable battery(s), a charger for portable batteries, a plug-in power supply, and a set of Transducer arrays (4) (Figure 1).
Figure 1: The NovoTTF-100A System components and assembly. (A) The transducer arrays are shown as they are applied to the scalp (1) with the array cables connected to the color-coded sockets on the connection cable and box (2). The box in turn is connected to the electric field generator with the battery as the power supply (3). (B) Transducer arrays showing ceramic discs and connector.
The authors have nothing to disclose.
NovoTTF-100A System | Novocure Limited | Portsmouth, NH | |
Bevacizumab (Avastin) | Genetech Corporation | South San Francisco, USA |